Objective — to analyze financial advisability of the administration of vedolizumab with selective intestinal effect compared with TNF-α inhibitors in the treatment of adults with moderate-to-severe UC and Crohn’s disease, unsatisfactory response to medication, loss of response or intolerance to prior therapy. Material and methods. The head of the organizational and methodological department for gastroenterology of the Research Institute for Health Care Organization and Medical Management provided data for analysis. Patients with inflammatory bowel diseases receiving medication at the expense of the Moscow budget fund were studied. Three-year direct medical costs of Moscow health care for biological therapy before and after the introduction of Vedolizumab for the treatment of adults with moderate-to-severe UC and CD were calculated. There were patients with an unsatisfactory response to medication, loss of response or intolerance to prior therapy. Results. Expansion of biological drug spectrum through the inclusion of vedolizumab with shares of 3.9, 7.9 and 11.8% for CD and 2, 7.2 and 10.8% for UC in the 1st, the 2nd, and the 3rd year, respectively. This will result in economic advantage for Moscow budget fund near 1 616 966.07 rubles in the treatment of UC and 141,555.67 rubles in the treatment of CD. Clinical and economic efficacy of primary administration of Vedolizumab was demonstrated in comparison with prescription of other TNF-α inhibitors. Perspectives for further development were determined to improve the quality of medical care for Moscow residents and increase the availability of biological drugs for patients with UC and CD. Conclusion. Administration of Vedolizumab in adults with moderate-to-severe UC and CD, unsatisfactory response to medication, loss of response or intolerance to previous therapy will improve financial efficiency of Moscow healthcare and availability of therapy for patients with these diseases.